By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BG Medicine today announced a collaboration with Boston Scientific to study whether galectin-3 can be used to screen patients for cardiac-resynchronization therapy.

Data for their effort will come from the MADIT-CRT study, the world's largest randomized study of New York Heart Association Class I and II patients. The study involves more than 1,800 patients enrolled in 110 centers worldwide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.